Celularity Business Summary

Celularity Inc. (CELU) is a clinical-stage biotechnology company that utilizes a proprietary platform to develop allogeneic, off-the-shelf therapies and biomaterial products derived from postpartum human placentas. The company generates revenue through three primary business segments: Bio-banking, which provides long-term storage of placental and umbilical cord tissues; Degenerative Disease, which commercializes advanced biomaterials such as Biovance, Interfyl, and FUSE Bone Void Filler; and Cell Therapy, which focuses on a clinical pipeline of natural killer (NK) cells and engineered T-cells. Celularity competes directly with other allogeneic cell therapy developers such as Caribou Biosciences, Fate Therapeutics, and Intellia Therapeutics. It distinguishes itself in the market by leveraging the unique immunological properties of placental-derived cells, which offer superior scalability and lower manufacturing complexity compared to the autologous (patient-specific) models utilized by many industry peers. The company was founded by Robert J. Hariri, M.D., Ph.D., who serves as Chairman and CEO and previously led Celgene Cellular Therapeutics as its CEO. The executive leadership team includes Dale A. Sander, who was appointed Executive Vice President and Chief Financial Officer in January 2026 following a tenure at Humacyte, and Bradley Glover, Ph.D., the Executive Vice President and Chief Operating Officer, who brings extensive technical operations experience from Kite Pharma. Other key figures include John R. Haines, Senior EVP and Chief Administrative Officer, and Anne Jones, Ph.D., the Chief Business Officer. Celularity’s board of directors features notable industry figures such as Peter H. Diamandis, M.D., and the company has secured significant recent backing from institutional investors including Philip A. Barach of DoubleLine Capital LP, alongside historical strategic support from Genting Berhad and Celgene.